Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 12/20 | 0.68 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.53 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.53 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.53 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.53 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.53 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.53 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.52 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.51 |
| ▸ | PPARD | Q03181 | 3/20 | 0.50 |
| ▸ | PPARA | Q07869 | 2/20 | 0.50 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.50 |
| ▸ | MMP13 | P45452 | 1/20 | 0.50 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.50 |
| ▸ | PPARG | P37231 | 1/20 | 0.49 |
| ▸ | RXRA | P19793 | 1/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.47 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12020986 | 1.00 | FFAR1 (0.68) | FFAR1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL12021108 | 0.91 | FFAR1 (0.64) | FFAR1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL3523470 | 0.91 | FFAR1 (0.66) | FFAR1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL12021068 | 0.91 | FFAR1 (0.63) | FFAR1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL13550323 | 0.90 | FFAR1 (0.79) | FFAR1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL13318254 | 0.90 | FFAR1 (0.62) | FFAR1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL14286071 | 0.90 | FFAR1 (0.62) | FFAR1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL14286192 | 0.90 | FFAR1 (0.62) | FFAR1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL13318209 | 0.87 | FFAR1 (0.59) | FFAR1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL13550339 | 0.86 | FFAR1 (0.74) | FFAR1MRGPRX4PPARDPPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137323-A1 | BENZO-FUSED COMPOUNDS FOR USE IN TREATING METABOLIC DISORDERS | AMGEN INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100137323-A1 | BENZO-FUSED COMPOUNDS FOR USE IN TREATING METABOLIC DISORDERS | AMGEN INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-7687526-B2 | Benzo-fused compounds for use in treating metabolic disorders | AMGEN INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-7687526-B2 | Benzo-fused compounds for use in treating metabolic disorders | AMGEN INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-20080119511-A1 | Benzo-fused compounds for use in treating metabolic disorders | AMGEN INC. (US) | 2008-05-22 | — | — | US | disclosed |
| US-20080119511-A1 | Benzo-fused compounds for use in treating metabolic disorders | AMGEN INC. (US) | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119511-A1 | Benzo-fused compounds for use in treating metabolic disorders | GOT2, PC, GLS2 | FFAR1 549/4885PSEN1 1251/4885PSEN2 782/4885 |
| US-20100137323-A1 | BENZO-FUSED COMPOUNDS FOR USE IN TREATING METABOLIC DISORDERS | GOT2, GLS2, PC | FFAR1 699/4885PSEN1 1028/4885PSEN2 823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.